Related references
Note: Only part of the references are listed.Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial
Jing He et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Low-dose IL-2 in children with recently diagnosed type 1 diabetes: a Phase I/II randomised, double-blind, placebo-controlled, dose-finding study
Michelle Rosenzwajg et al.
DIABETOLOGIA (2020)
An IL-2 mutein engineered to promote expansion of regulatory T cells arrests ongoing autoimmunity in mice
Liliane Khoryati et al.
SCIENCE IMMUNOLOGY (2020)
Low dose of IL-2 combined with rapamycin restores and maintains the long-term balance of Th17/Treg cells in refractory SLE patients
Chunmiao Zhao et al.
BMC IMMUNOLOGY (2019)
Mucosal-Associated Invariant T Cell Features and TCR Repertoire Characteristics During the Course of Multiple Sclerosis
Edgar Carnero Contentti et al.
FRONTIERS IN IMMUNOLOGY (2019)
Mucosal-associated invariant T cells and disease
Amine Toubal et al.
NATURE REVIEWS IMMUNOLOGY (2019)
Low-dose interleukin-2 as a modulator of Treg homeostasis after HSCT: current understanding and future perspectives
Ken-ichi Matsuoka
INTERNATIONAL JOURNAL OF HEMATOLOGY (2018)
Multiplexed droplet single-cell RNA-sequencing using natural genetic variation
Hyun Min Kang et al.
NATURE BIOTECHNOLOGY (2018)
A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism
Eleonora Trotta et al.
NATURE MEDICINE (2018)
Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes
Jonathan T. Sockolosky et al.
SCIENCE (2018)
Reprogramming human T cell function and specificity with non-viral genome targeting
Theodore L. Roth et al.
NATURE (2018)
Revisiting IL-2: Biology and therapeutic prospects
Abul K. Abbas et al.
SCIENCE IMMUNOLOGY (2018)
Biology and regulation of IL-2: from molecular mechanisms to human therapy
Rosanne Spolski et al.
NATURE REVIEWS IMMUNOLOGY (2018)
SCANPY: large-scale single-cell gene expression data analysis
F. Alexander Wolf et al.
GENOME BIOLOGY (2018)
Discovery of stimulation-responsive immune enhancers with CRISPR activation
Dimitre R. Simeonov et al.
NATURE (2017)
Cytotoxic and regulatory roles of mucosal-associated invariant T cells in type 1 diabetes
Ophelie Rouxel et al.
NATURE IMMUNOLOGY (2017)
Systemic Immunity Is Required for Effective Cancer Immunotherapy
Matthew H. Spitzer et al.
CELL (2017)
Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease
John Koreth et al.
BLOOD (2016)
NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
Deborah H. Charych et al.
CLINICAL CANCER RESEARCH (2016)
Interleukin-1 antagonism moderates the inflammatory state associated with Type 1 diabetes during clinical trials conducted at disease onset
Susanne M. Cabrera et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2016)
Using GWAS to identify genetic predisposition in hepatic autoimmunity
G. J. Webb et al.
JOURNAL OF AUTOIMMUNITY (2016)
Technical Advance: Human MAIT-cell responses to Escherichia coli: activation, cytokine production, proliferation, and cytotoxicity
Joana Dias et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2016)
Factors affecting long-term efficacy of T regulatory cell-based therapy in type 1 diabetes
Natalia Marek-Trzonkowska et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2016)
Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial
John A. Todd et al.
PLOS MEDICINE (2016)
Regulatory T cell memory
Michael D. Rosenblum et al.
NATURE REVIEWS IMMUNOLOGY (2016)
Low-dose IL-2 selectively activates subsets of CD4+ Tregs and NK cells
Masahiro Hirakawa et al.
JCI INSIGHT (2016)
Selective IL-2 Responsiveness of Regulatory T Cells Through Multiple Intrinsic Mechanisms Supports the Use of Low-Dose IL-2 Therapy in Type 1 Diabetes
Aixin Yu et al.
DIABETES (2015)
Current State of Type 1 Diabetes Treatment in the US: Updated Data From the T1D Exchange Clinic Registry
Kellee M. Miller et al.
DIABETES CARE (2015)
Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients
Michelle Rosenzwajg et al.
JOURNAL OF AUTOIMMUNITY (2015)
Thymic regulatory T cell niche size is dictated by limiting IL-2 from antigen-bearing dendritic cells and feedback competition
Brian M. Weist et al.
NATURE IMMUNOLOGY (2015)
Palladium-based mass tag cell barcoding with a doublet-filtering scheme and single-cell deconvolution algorithm
Eli R. Zunder et al.
NATURE PROTOCOLS (2015)
Type 1 diabetes immunotherapy using polyclonal regulatory T cells
Jeffrey A. Bluestone et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Effects of Low-Dose Recombinant Interleukin 2 to Promote T-Regulatory Cells in Alopecia Areata
Emeline Castela et al.
JAMA DERMATOLOGY (2014)
Normalization of mass cytometry data with bead standards
Rachel Finck et al.
CYTOMETRY PART A (2013)
The Prevalence of Type 1 Diabetes in the United States
Andy Menke et al.
EPIDEMIOLOGY (2013)
Interleukin-2 at the Crossroads of Effector Responses, Tolerance, and Immunotherapy
Wei Liao et al.
IMMUNITY (2013)
Antigen-loaded MR1 tetramers define T cell receptor heterogeneity in mucosal-associated invariant T cells
Rangsima Reantragoon et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials
Antoinette Moran et al.
LANCET (2013)
Low-Dose Interleukin-2 Therapy Restores Regulatory T Cell Homeostasis in Patients with Chronic Graft-Versus-Host Disease
Ken-ichi Matsuoka et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Regulatory T-Cell Therapy in Transplantation: Moving to the Clinic
Qizhi Tang et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2013)
Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial
Agnes Hartemann et al.
LANCET DIABETES & ENDOCRINOLOGY (2013)
Rapamycin/IL-2 Combination Therapy in Patients With Type 1 Diabetes Augments Tregs Yet Transiently Impairs β-cell Function
S. Alice Long et al.
DIABETES (2012)
The role of interleukin-2 during homeostasis and activation of the immune system
Onur Boyman et al.
NATURE REVIEWS IMMUNOLOGY (2012)
Plasticity of Human Regulatory T Cells in Healthy Subjects and Patients with Type 1 Diabetes
Stephanie A. McClymont et al.
JOURNAL OF IMMUNOLOGY (2011)
Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-Induced Vasculitis
David Saadoun et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
John Koreth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Defects in IL-2R Signaling Contribute to Diminished Maintenance of FOXP3 Expression in CD4+ CD25+ Regulatory T-Cells of Type 1 Diabetic Subjects
S. Alice Long et al.
DIABETES (2010)
IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells
Yenkel Grinberg-Bleyer et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Cutting Edge: Increased IL-17-Secreting T Cells in Children with New-Onset Type 1 Diabetes
Ashish K. Marwaha et al.
JOURNAL OF IMMUNOLOGY (2010)
Cutting Edge: Mechanisms of IL-2-Dependent Maintenance of Functional Regulatory T Cells
Luke Barron et al.
JOURNAL OF IMMUNOLOGY (2010)
Genetics, pathogenesis and clinical interventions in type 1 diabetes
Jeffrey A. Bluestone et al.
NATURE (2010)
Mechanisms of impaired regulation by CD4+CD25+FOXP3+ regulatory T cells in human autoimmune diseases
Jane Hoyt Buckner
NATURE REVIEWS IMMUNOLOGY (2010)
A Low Interleukin-2 Receptor Signaling Threshold Supports the Development and Homeostasis of T Regulatory Cells
Aixin Yu et al.
IMMUNITY (2009)
Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction
Qizhi Tang et al.
IMMUNITY (2008)
The Effector T Cells of Diabetic Subjects Are Resistant to Regulation via CD4+FOXP3+ Regulatory T Cells
Anya Schneider et al.
JOURNAL OF IMMUNOLOGY (2008)
Selective availability of IL-2 is a major determinant controlling the production of CD4+CD25+Foxp3+ T regulatory cells
Aixin Yu et al.
JOURNAL OF IMMUNOLOGY (2006)
Sequential development of interleukin 2 dependent effector and regulatory T cells in response to endogenous systemic antigen
B Knoechel et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
A function for interleukin 2 in Foxp3-expressing regulatory T cells
JD Fontenot et al.
NATURE IMMUNOLOGY (2005)
Functional defects and the influence of age on the frequency of CD4+CD25+ T-Cells in type 1 diabetes
TM Brusko et al.
DIABETES (2005)
Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes
S Lindley et al.
DIABETES (2005)
Share Paper
